The Safety of Intrathecal Therapy in the Treatment of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)Phavina A Akhom, Adetola A. Kassim, Reena Jayani et al.|Transplantation and Cellular Therapy|2025Cited by 2
Outcomes Following Graft Failure and Second Subsequent Allogeneic Hematopoietic Cell Transplant in Patients with Sickle Cell Disease: A Multicenter StudyHemalatha G. Rangarajan, Allistair Abraham, Elizabeth O. Stenger et al.|Transplantation and Cellular Therapy|2026Cited by 1
Feasibility of outpatient administration of ciltacabtagene autoleucel and reduction in healthcare utilization cost: the Vanderbilt experienceIhunayachi Ohuabunwa, Olalekan O. Oluwole, B Dholaria et al.|Bone Marrow Transplantation|2025Cited by 0
ABO Incompatibility Did Not Impact Outcomes after Haploidentical Bone Marrow Transplantation with Posttransplant Cyclophosphamide for Patients with Sickle Cell Disease: Single Center ExperienceDanielle Murphy, Adetola A. Kassim, Karina Wilkerson et al.|Transplantation and Cellular Therapy|2023Cited by 0
Outpatient Chimeric Antigen Receptor T cell Therapy in Patients Who Resided at Their Home Compared to Hospital-Provided Housing: A Single Institution ExperienceEmmanuella Iyore Osamuyi, Eden Biltibo, Grace Johnson Mercadante et al.|Transplantation and Cellular Therapy|2026Cited by 0